Innate Pharma Investor Relations Material
Latest events
Q4 2023
Innate Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Innate Pharma S.A.
Access all reports
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications. It generates its products from the expression platforms based on its phage display and dAb technologies. The company's lead product is NexoBrid, which is a treatment for severe burns that can be used outside of the European Union; and Phase 3 NExoBrid clinical trial is completed in Europe. Innate Pharma S.A. was founded in 2000 as Innate ImmunoPharmaceuticals S.A.; and it changed its name to Innate Pharma S.A. in 2011. Innate Pharma S.A. has operations in Saint Prex, Switzerland; and Sophia Antipolis, France. Innate Pharma S.A is based in Marseille, France.
Latest articles
From Timber to Luxury: The Story of François-Henri Pinault and Kering
Dive into the story of François-Henri Pinault, from his rise in the family timber business to leading Kering into a global luxury powerhouse.
7 May 2024
Companies That Had Their IPO in 1994: A Cautious Market
An overview of the year 1994 in the stock and IPO market, as the interest rates soared and the bond market collapsed.
6 May 2024
The World of Luxury: Creating and Selling Desirability
Dive into the enchanting world of high-end allure, where the art of exclusivity shapes desire, turning luxury into an emblem of unique prestige.
6 May 2024
Ticker symbol
Country
🇫🇷 France